866-997-4948(US-Canada Toll Free)

Irritable Bowel Syndrome - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 140 Pages

Irritable Bowel Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome - Overview 11
Irritable Bowel Syndrome - Therapeutics under Development by Companies 12
Irritable Bowel Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Irritable Bowel Syndrome - Products under Development by Companies 17
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19
4D Pharma Plc 19
A. Menarini Industrie Farmaceutiche Riunite Srl 20
Alfa Wassermann S.p.A 21
Ardelyx, Inc. 22
Astellas Pharma Inc. 23
CJ HealthCare Corp. 24
Dong-A Socio Holdings Co. Ltd. 25
Enterome Bioscience SA 26
GlaxoSmithKline Plc 27
Innovative Med Concepts, LLC 28
Ironwood Pharmaceuticals, Inc. 29
Kissei Pharmaceutical Co., Ltd. 30
Lexicon Pharmaceuticals, Inc. 31
Napo Pharmaceuticals Inc 32
Ono Pharmaceutical Co., Ltd. 33
Pfizer Inc. 34
RaQualia Pharma Inc. 35
RedHill Biopharma Ltd. 36
SK Biopharmaceuticals Co., Ltd. 37
Sumitomo Dainippon Pharma Co Ltd 38
Synergy Pharmaceuticals, Inc. 39
Synthetic Biologics, Inc. 40
Vitality Biopharma Inc 41
Irritable Bowel Syndrome - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
(celecoxib + famciclovir) - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ASP-1017 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ASP-7147 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
bedoradrine sulfate - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Blautix - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CJ-14199 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
crofelemer DR - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
CSTI-300 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
DA-6886 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
DSP-6952 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
EB-420 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
GSK-3179106 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
ibodutant - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
linaclotide - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
lovastatin - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
LT-4006 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
LX-1033 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
ondansetron hydrochloride CR - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
ONO-2952 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
ORP-101 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
PBF-677 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
plecanatide - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
pregabalin - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
relenopride hydrochloride - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
rifaximin - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
RQ-00202730 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
RQ-00310941 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
solabegron hydrochloride - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
tenapanor hydrochloride - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
VB-210 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Irritable Bowel Syndrome - Dormant Projects 120
Irritable Bowel Syndrome - Discontinued Products 125
Irritable Bowel Syndrome - Product Development Milestones 126
Featured News & Press Releases 126
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 126
Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting 127
Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting 128
Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program 129
Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation 130
Jul 19, 2016: 4D Pharma Provides Phase I Clinical Trial Update 130
Jul 15, 2016: Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program 131
Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for IBS-D 132
May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin 133
May 23, 2016: Phase I trial Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma 133
May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 134
May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016 135
May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 136
May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016 136
May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development 137
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 139
Disclaimer 140

List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Development by Companies, H2 2016 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2016 19
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016 20
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H2 2016 21
Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H2 2016 22
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H2 2016 23
Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H2 2016 24
Irritable Bowel Syndrome - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 25
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2016 26
Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 27
Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts, LLC, H2 2016 28
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 29
Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 30
Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 31
Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2016 32
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 33
Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H2 2016 34
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H2 2016 35
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H2 2016 36
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 37
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 38
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016 39
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H2 2016 40
Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2016 41
Assessment by Monotherapy Products, H2 2016 42
Assessment by Combination Products, H2 2016 43
Number of Products by Stage and Target, H2 2016 45
Number of Products by Stage and Mechanism of Action, H2 2016 47
Number of Products by Stage and Route of Administration, H2 2016 50
Number of Products by Stage and Molecule Type, H2 2016 52
Irritable Bowel Syndrome - Dormant Projects, H2 2016 120
Irritable Bowel Syndrome - Dormant Projects (Contd..1), H2 2016 121
Irritable Bowel Syndrome - Dormant Projects (Contd..2), H2 2016 122
Irritable Bowel Syndrome - Dormant Projects (Contd..3), H2 2016 123
Irritable Bowel Syndrome - Dormant Projects (Contd..4), H2 2016 124
Irritable Bowel Syndrome - Discontinued Products, H2 2016 125

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 42
Number of Products by Top 10 Targets, H2 2016 44
Number of Products by Stage and Top 10 Targets, H2 2016 44
Number of Products by Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Routes of Administration, H2 2016 49
Number of Products by Stage and Routes of Administration, H2 2016 49
Number of Products by Molecule Types, H2 2016 51
Number of Products by Stage and Molecule Types, H2 2016 51

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *